FindTrial
Sign In

Intracameral different dosage triamcinolone acetonide preventing anterior uveitis after uveitic cataract

Intracameral different dosage triamcinolone acetonide preventing anterior uveitis after uveitic cataract

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003466
Enrollment
Unknown
Registered
2013-08-16
Start date
2013-09-02
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cataract

Interventions

1:intracameral triamcinolone acetonide 1.0mg in phacoemulsification
2:intracameral triamcinolone acetonide 2.0mg in phacoemulsification
3:intracameral triamcinolone acetonide 4.0mg in phacoemulsification

Sponsors

Beijing Shijitan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Over 40 years of age; 2. Patients with visually significant cataract with the best corrected visual acuity less than 0.5; 3. Nonspecific chronic recurrent anterior uveitis, intermediate uveitis.

Exclusion criteria

Exclusion criteria: 1) Patients with glaucoma; 2) Past medical history of intraocular surgery; 3) Patients taking systemic immunosuppressants or adrenal corticosteroid.

Design outcomes

Primary

MeasureTime frame
Visual Acuity;Intraocular Pressure;—

Countries

China

Contacts

Public ContactDong Ning
dongning0208@163.com+86 13910435129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026